Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation

Completed 20 enrolled Institute for Clinical and Experimental Medicine Charite University, Berlin, Germany · collab Miltenyi Biomedicine GmbH · collab

RandomizedParallel-groupOpen-labelScreening

Summary

The aim of the study is to evaluate the efficacy of new immunosuppressive protocol based on two applications of anti-CD52 MabCampath (Alemtuzumab) a single dose of anti-TNF-α Remicade (infliximab) monoclonal antibodies in the early posttransplant period followed by either monotherapy based on tacrolimus or sirolimus.

Timeline

Start: 2007-01
Primary completion: 2009-03
Completion: 2009-03

Publications

Results Viklicky O, Hruba P, Tomiuk S, Schmitz S, Gerstmayer B, Sawitzki B, Miqueu P, Mrazova P, Tycova I, Svobodova E, Honsova E, Janssen U, Volk HD, Reinke P. Sequential Targeting of CD52 and TNF Allows Early Minimization Therapy in Kidney Transplantation: From a Biomarker to Targeting in a Proof-Of-Concept Trial. PLoS One. 2017 Jan 13;12(1):e0169624. doi: 10.1371/journal.pone.0169624. eCollection 2017.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Sirolimus	Small molecule	—	—
Comparator	Tacrolimus	Small molecule	—	—
Comparator	Alemtuzumab	Monoclonal antibody	20 mg	—
Comparator	Infliximab	Monoclonal antibody	5 mg/kg	—

Indications

No indication recorded.